Current Atherosclerosis Reports

, Volume 12, Issue 2, pp 88–95 | Cite as

A Cardiologist’s View of Hypoglycemia

  • Shailesh Nandish
  • Jamison Wyatt
  • Rene Oliveros
  • Adrienne Stevens Zion
  • Michael Lujan
  • Robert ChiltonEmail author


Recent studies have failed to show an improvement in cardiovascular mortality with intensive glycemic control and aggressive glycated hemoglobin (A1c) targets less than 7.0%. Excessive hypoglycemic episodes with intensive glucose-lowering therapy are thought to be a major factor in the failure to show cardiovascular benefit in these trials. In this article, we review the physiology of glucose metabolism, the cardiovascular pathophysiology of hypoglycemia, and the trials with an intensive glucose-lowering strategy that have studied microvascular and macrovascular complications. We also review the current non-insulin drugs available for the treatment of diabetes and their potential hypoglycemic and cardiovascular impacts.


Diabetes Hypoglycemia Cardiology 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interests, published recently, have been highlighted as: • Of importance

  1. 1.
    Cryer PE: Hypoglycemia. Pathophysiology, Diagnosis, and Treatment. New York: Oxford University Press; 1997.Google Scholar
  2. 2.
    Carroll MF, Burge MR, Schade DS: Severe hypoglycemia in adults. Rev Endocr Metab Disord 2003, 4:149–157.CrossRefPubMedGoogle Scholar
  3. 3.
    Aronoff SL, Berkowitz K, Shreiner B, Want L: Glucose metabolism and regulation: beyond insulin and glucagon diabetes. Spectrum 2004, 17:183–190.CrossRefGoogle Scholar
  4. 4.
    Matyka K, Evans M, Lomas J, et al.: Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997, 20:135–141.CrossRefPubMedGoogle Scholar
  5. 5.
    McCrimmon RJ, Frier BM: Symptomatic and physiologic responses to hypoglycemia induced by human soluble insulin and the analogue lispro human insulin. Diabetes Med 1997, 14:929–936.CrossRefGoogle Scholar
  6. 6.
    Neubauer S: Mechanisms of disease: the failing heart—an engine out of fuel. N Engl J Med 2007, 356:1140–1151.CrossRefPubMedGoogle Scholar
  7. 7.
    Bertrand L, Horman S, Beauloye C, Vanoverschelde JL: Insulin signaling in the heart. Cardiovasc Res 2008, 79:238–248.CrossRefPubMedGoogle Scholar
  8. 8.
    Dyck JR, Lopaschuk GD: AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2007, 574:95–112.CrossRefGoogle Scholar
  9. 9.
    • Patterson B; Fields AV, Richard S: New insights into myocardial glucose metabolism: surviving under stress. Curr Opin Clin Nutr Metab Care 2009, 12:424–430. This article points out many important metabolic changes in myocardial metabolism during stress.Google Scholar
  10. 10.
    Ban K, Noyan-Ashraf MH, Hoefer J: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2361.CrossRefGoogle Scholar
  11. 11.
    Cryer PE: Clinical Practice Guideline: Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009, 94:709–728.CrossRefPubMedGoogle Scholar
  12. 12.
    Ernstene AC, Altschule MD: The effect of insulin hypoglycemia on the circulation. J Clin Invest 1931, 10:521.CrossRefPubMedGoogle Scholar
  13. 13.
    Jensen J: The adrenalin test in hypertension. Am Heart J 1930, 5:763.CrossRefGoogle Scholar
  14. 14.
    Euler U, Liljestrand G, Skandinav D: Die Wirkung des adrenalins auf das minutenvolumen des herzens beim menschen [German]. Arch Physiol 1927, 52:243.Google Scholar
  15. 15.
    Read RS, Doherty JE: Cardiovascular effects of induced insulin hypoglycemia in man during the Hollander test. Am J Surg 1970, 119:155–162.CrossRefPubMedGoogle Scholar
  16. 16.
    Koivikko M, Koivikko ML, Salmela PI, et al.: Effects of sustained insulin induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes 2005, 54:744–750.CrossRefPubMedGoogle Scholar
  17. 17.
    Ziegler D: Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994, 10:339383.CrossRefPubMedGoogle Scholar
  18. 18.
    Ziegler D: Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Rev 1999, 7:300315.Google Scholar
  19. 19.
    Vinik SI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy Diabetes Care 2003, 26:1553–1579.Google Scholar
  20. 20.
    Mudaliar S: Serum glucose control in diabetic patients with cardiovascular disease: should we be less aggressive? Curr Atheroscler Rep 2009, 11:384–903CrossRefPubMedGoogle Scholar
  21. 21.
    • Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559. This is an important trial in regard to increased cardiovascular events in the intensive-treatment arm and increased hypoglycemic events overall.Google Scholar
  22. 22.
    • ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572. This is a recent pivotal trial that looked at cardiovascular outcomes with intensive glucose-lowering therapy.Google Scholar
  23. 23.
    • Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139. This is an important trial with the additional concern of weight gain and hypoglycemia with increasing insulin.Google Scholar
  24. 24.
    Group AC, Patel A, MacMahon S, et al; ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.CrossRefGoogle Scholar
  25. 25.
    American Heart Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941–2948.CrossRefGoogle Scholar
  26. 26.
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.CrossRefPubMedGoogle Scholar
  27. 27.
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  28. 28.
    UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.CrossRefGoogle Scholar
  29. 29.
    Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.CrossRefPubMedGoogle Scholar
  30. 30.
    Inzucchi SE, Maggs DG, Spollett GR, et al.: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338:867–872.CrossRefPubMedGoogle Scholar
  31. 31.
    Klepzig H, Kober G, Matter C, et al.: Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20:403–405.CrossRefGoogle Scholar
  32. 32.
    Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987, 36:689–692.CrossRefPubMedGoogle Scholar
  33. 33.
    Tushuizen ME, Bunck MC, Pouwels PJ, et al.: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015–1017.CrossRefPubMedGoogle Scholar
  34. 34.
    Wright AF: Moving forward on research. Br J Gen Pract 1991, 41:178–179.PubMedGoogle Scholar
  35. 35.
    Cryer PE: Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008, 14:750–756.PubMedGoogle Scholar
  36. 36.
    Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53:298–304.CrossRefPubMedGoogle Scholar
  37. 37.
    McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Shailesh Nandish
    • 1
  • Jamison Wyatt
    • 1
  • Rene Oliveros
    • 1
  • Adrienne Stevens Zion
    • 2
  • Michael Lujan
    • 1
  • Robert Chilton
    • 1
    Email author
  1. 1.Cardiovascular Diseases, Division of Cardiology, MC 7872UT Health Science CenterSan AntonioUSA
  2. 2.Teachers CollegeColumbia UniversityNew YorkUSA

Personalised recommendations